High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation

High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation

Abstract Background High-dose chemotherapy with autologous stem cell rescue (HDCT) is a promising treatment for patients with stage III, HER2-negative, homologous recombination deficient (HRD) breast cancer. Clinical effectiveness and cost-effectiveness are currently under investigation in an intern...

Full description

Bibliographic Details
Main Authors: Joost G. E. Verbeek, Vincent M. T. de Jong, Hanna M. Wijnja, Agnes Jager, Sabine C. Linn, Valesca P. Retèl, Wim H. van Harten
Format: Article
Language:English
Published: BMC 2023-01-01
Series:BMC Cancer
Subjects:
Breast Neoplasms
Homologous Recombination
Drug Therapy
Translational Research
Qualitative Research
Implementation Science
Online Access:https://doi.org/10.1186/s12885-022-10412-x

Internet

https://doi.org/10.1186/s12885-022-10412-x

Similar Items